Form 4: Nuo Therapeutics Director Charles E. Sheedy Acquires 100,000 Shares

Director Charles E. Sheedy reports the acquisition of 100,000 shares of Nuo Therapeutics, Inc. at $0.75 per share.

Summary

• Charles E. Sheedy, a director of Nuo Therapeutics, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction on May 20, 2024, where Sheedy acquired 100,000 shares of Common Stock at a price of $0.75 per share.
• Following the transaction, Sheedy directly owns 11,312,500 shares.
• Sheedy also indirectly owns 3,365 shares held in separate trusts for the benefit of his children.
• The reporting person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a stock purchase by a director. The purchase itself could be interpreted as slightly positive, indicating confidence, but the document is primarily informational.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Management Comments

• The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein.

Industry Context

This filing is a routine disclosure required by the SEC for corporate insiders. It provides transparency into the trading activities of individuals with access to non-public information.

Stakeholder Impact

• Shareholders may view the director's stock purchase as a positive signal.

Key Dates